Development of a novel recombinant biotherapeutic with applications in targeted therapy of human arthritis

Arthritis and Rheumatism

Volumn 63, Issue 12, 2011, Pages 3758-3767

  Kamperidis, Panagiotis ^a   Kamalati, Tahereh ^a   Ferrari, Mathieu ^a   Jones, Margaret ^a   Garrood, Toby ^a   Smith, Malcolm D ^b   Diez Posada, Soraya ^c   Hughes, Chris ^a   Finucane, Ciara ^a   Mather, Stephen ^a   Nissim, Ahuva ^a   George, Andrew J T ^d   Pitzalis, Costantino ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY A7; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTHRITIS; ARTICLE; BIOTINYLATION; DRUG BINDING; DRUG TARGETING; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INFLAMMATORY DISEASE; MICROVASCULATURE; MOUSE; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANIMALS; ANTIBODY SPECIFICITY; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; EPITOPES; HUMANS; MICE; MICE, SCID; MICROVESSELS; OSTEOARTHRITIS; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; SYNOVIAL MEMBRANE; TRANSPLANTATION, HETEROLOGOUS;

EID: 82455210374     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30650     Document Type: Article

References (48)

1. Callahan LF,. Awareness of the prevalence and impact of arthritis: the role of health professionals [editorial]. Arthritis Care Res 1995; 8: 63-5.
2. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, et al. Mortality in rheumatoid arthritis: increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007; 46: 350-7. (Pubitemid 46189799)
3. Paleolog EM,. Angiogenesis in rheumatoid arthritis. Arthritis Res 2002; 4: S81-90.
4. Choy EH, Panayi GS,. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16. (Pubitemid 32224400)
5. Szekanecz Z, Koch AE,. Vascular involvement in rheumatic diseases: 'vascular rheumatology.' Arthritis Res Ther 2008; 10: 224.
6. Paleolog EM,. The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol 2009; 90: 249-61.
7. Hirohata S, Sakakibara J,. Angioneogenesis as a possible elusive triggering factor in rheumatoid arthritis. Lancet 1999; 353: 1331. (Pubitemid 29178791)
8. Clavel G, Bessis N, Lemeiter D, Fardellone P, Mejjad O, Menard JF, et al. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol 2007; 124: 158-64. (Pubitemid 47059038)
9. Khong TL, Larsen H, Raatz Y, Paleolog E,. Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. Angiogenesis 2007; 10: 243-58. (Pubitemid 350045884)
10. Lainer-Carr D, Brahn E,. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol 2007; 3: 434-42. (Pubitemid 47193549)
11. Szekanecz Z, Besenyei T, Paragh G, Koch AE,. New insights in synovial angiogenesis. Joint Bone Spine 2010; 77: 13-9.
12. Rothe A, Power BE, Hudson PJ,. Therapeutic advances in rheumatology with the use of recombinant proteins. Nat Clin Pract Rheumatol 2008; 4: 605-14.
13. Kremer JM,. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001; 134: 695-706. (Pubitemid 32322246)
14. Taylor PC, Feldmann M,. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 578-82.
15. Khraishi M,. Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl 2009; 82: 25-32.
16. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ,. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010; 9: 325-38.
17. Garrood T, Blades M, Haskard DO, Mather S, Pitzalis C,. A novel model for the pre-clinical imaging of inflamed human synovial vasculature. Rheumatology (Oxford) 2009; 48: 926-31.
18. Lee L, Buckley C, Blades MC, Panayi G, George AJ, Pitzalis C,. Identification of synovium-specific homing peptides by in vivo phage display selection. Arthritis Rheum 2002; 46: 2109-20.
19. George AJ, Lee L, Pitzalis C,. Isolating ligands specific for human vasculature using in vivo phage selection. Trends Biotechnol 2003; 21: 199-203. (Pubitemid 36515072)
20. Wahid S, Blades MC, De Lord D, Brown I, Blake G, Yanni G, et al. Tumour necrosis factor-alpha (TNF-α) enhances lymphocyte migration into rheumatoid synovial tissue transplanted into severe combined immunodeficient (SCID) mice. Clin Exp Immunol 2000; 122: 133-42.
21. De Wildt RM, Mundy CR, Gorick BD, Tomlinson IM,. Antibody arrays for high-throughput screening of antibody-antigen interactions. Nat Biotechnol 2000; 18: 989-94. (Pubitemid 32977382)
22. Hughes C, Faurholm B, Dell'Accio F, Manzo A, Seed M, Eltawil N, et al. Human single-chain variable fragment that specifically targets arthritic cartilage. Arthritis Rheum 2010; 62: 1007-16.
23. Goletz S, Christensen PA, Kristensen P, Blohm D, Tomlinson I, Winter G, et al. Selection of large diversities of antiidiotypic antibody fragments by phage display. J Mol Biol 2002; 315: 1087-97. (Pubitemid 34729288)
24. Harrison JL, Williams SC, Winter G, Nissim A,. Screening of phage antibody libraries. Methods Enzymol 1996; 267: 83-109. (Pubitemid 26159217)
25. 131I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN. J Nucl Med 2001; 42: 509-19. (Pubitemid 32207405)
26. Barlow AL, Macleod A, Noppen S, Sanderson J, Guerin CJ,. Colocalization analysis in fluorescence micrographs: verification of a more accurate calculation of Pearson's correlation coefficient. Microsc Microanal 2010; 16: 710-24.
27. Adler J, Parmryd I,. Quantifying colocalization by correlation: the Pearson correlation coefficient is superior to the Mander's overlap coefficient. Cytometry A 2010; 77: 733-42.
28. Smith MD, Barg E, Weedon H, Papengelis V, Smeets T, Tak PP, et al. Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. Ann Rheum Dis 2003; 62: 303-7. (Pubitemid 36363434)
29. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis [published erratum appears in Arthritis Rheum 2010;62:3005]. Arthritis Rheum 2009; 60: 2272-83.
30. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68: 789-96.
31. Van Vollenhoven RF,. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009; 5: 531-41.
32. Lipsky PE,. Are new agents needed to treat RA? Nat Rev Rheumatol 2009; 5: 521-2.
33. Szekanecz Z, Besenyei T, Szentpetery A, Koch AE,. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr Opin Rheumatol 2010; 22: 299-306.
34. Middleton J, Americh L, Gayon R, Julien D, Aguilar L, Amalric F, et al. Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky. Arthritis Res Ther 2004; 6: 60-72. (Pubitemid 38444463)
35. Pitzalis C, Garrood T,. From ubiquitous antigens to joint-specific inflammation: could local vascular permeability be the missing link? Trends Immunol 2006; 27: 299-302. (Pubitemid 43963477)
36. Alam C, Colville-Nash P, Seed M,. Modelling angiogenesis in inflammation. In:, Seed MP, Walsh DA, editors. Angiogenesis in inflammation: mechanisms and clinical correlates. Basel: Birkhauser Verlag; 2008. p. 99-148.
37. Rybak JN, Trachsel E, Scheuermann J, Neri D,. Ligand-based vascular targeting of disease. ChemMedChem 2007; 2: 22-40.
38. Trachsel E, Bootz F, Silacci M, Kaspar M, Kosmehl H, Neri D,. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther 2007; 9: R9.
39. Schliemann C, Neri D,. Antibody-based vascular tumor targeting. Recent Results Cancer Res 2010; 180: 201-16.
40. Trachsel E, Kaspar M, Bootz F, Detmar M, Neri D,. A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo. J Invest Dermatol 2007; 127: 881-6. (Pubitemid 46434663)
41. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, et al. Design and use of a phage display library: human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998; 273: 21769-76. (Pubitemid 28405353)
42. Menrad A, Menssen HD,. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets 2005; 9: 491-500. (Pubitemid 40883149)
43. Dela Cruz JS, Huang TH, Penichet ML, Morrison SL,. Antibody-cytokine fusion proteins: innovative weapons in the war against cancer. Clin Exp Med 2004; 4: 57-64. (Pubitemid 39506597)
44. Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 2009; 11: R142.
45. Pfaffen S, Hemmerle T, Weber M, Neri D,. Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3. Exp Cell Res 2009; 316: 836-47.
46. Chames P, Baty D,. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 2009; 1: 539-47.
47. Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR. MAbs 2009; 1: 128-41.
48. Mabry R, Lewis KE, Moore M, McKernan PA, Bukowski TR, Bontadelli K, et al. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng Des Sel 2010; 23: 115-27.